Conduit Pharmaceuticals (CDT) Competitors $2.52 -0.24 (-8.70%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CDT vs. PRAX, XNCR, ARDX, DAWN, ANIP, ARVN, RCUS, OCUL, SNDX, and CALTShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include Praxis Precision Medicines (PRAX), Xencor (XNCR), Ardelyx (ARDX), Day One Biopharmaceuticals (DAWN), ANI Pharmaceuticals (ANIP), Arvinas (ARVN), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Syndax Pharmaceuticals (SNDX), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Praxis Precision Medicines Xencor Ardelyx Day One Biopharmaceuticals ANI Pharmaceuticals Arvinas Arcus Biosciences Ocular Therapeutix Syndax Pharmaceuticals Calliditas Therapeutics AB (publ) Conduit Pharmaceuticals (NASDAQ:CDT) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings. Which has higher valuation and earnings, CDT or PRAX? Conduit Pharmaceuticals has higher earnings, but lower revenue than Praxis Precision Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$540KN/AN/APraxis Precision Medicines$2.45M570.46-$123.28M-$10.30-7.28 Does the media prefer CDT or PRAX? In the previous week, Conduit Pharmaceuticals had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Conduit Pharmaceuticals and 3 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.69 beat Conduit Pharmaceuticals' score of 0.46 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conduit Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor CDT or PRAX? Praxis Precision Medicines received 42 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Conduit Pharmaceuticals an outperform vote while only 72.88% of users gave Praxis Precision Medicines an outperform vote. CompanyUnderperformOutperformConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesPraxis Precision MedicinesOutperform Votes4372.88% Underperform Votes1627.12% Is CDT or PRAX more profitable? Conduit Pharmaceuticals has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Conduit Pharmaceuticals' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -328.67% Praxis Precision Medicines -9,409.22%-54.86%-50.52% Which has more volatility & risk, CDT or PRAX? Conduit Pharmaceuticals has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.66, meaning that its stock price is 166% more volatile than the S&P 500. Do analysts prefer CDT or PRAX? Praxis Precision Medicines has a consensus price target of $149.11, suggesting a potential upside of 98.87%. Given Praxis Precision Medicines' higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Praxis Precision Medicines 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Do institutionals & insiders believe in CDT or PRAX? 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 30.9% of Conduit Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryConduit Pharmaceuticals and Praxis Precision Medicines tied by winning 8 of the 16 factors compared between the two stocks. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$283.87M$6.76B$5.53B$9.06BDividend YieldN/A2.94%5.36%3.96%P/E RatioN/A9.9089.6417.39Price / SalesN/A336.881,280.51135.03Price / CashN/A65.0944.3037.67Price / Book-276.005.215.054.66Net Income-$540,000.00$154.35M$117.51M$224.41M7 Day Performance-44.80%2.17%1.47%-0.70%1 Month Performance-63.73%2.54%4.38%0.99%1 Year Performance-99.02%7.76%25.65%18.05% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit PharmaceuticalsN/A$2.52-8.7%N/A-99.1%$259.70MN/A0.003Stock SplitShort Interest ↓PRAXPraxis Precision Medicines2.0616 of 5 stars$72.28-6.3%$149.11+106.3%+81.7%$1.34B$2.45M-7.00110Short Interest ↑XNCRXencor4.2764 of 5 stars$19.15-2.5%$34.88+82.1%-8.1%$1.34B$168.34M-6.00280Positive NewsARDXArdelyx3.8663 of 5 stars$5.54+0.3%$9.42+70.0%-41.9%$1.31B$124.46M-18.4490Analyst ForecastAnalyst RevisionDAWNDay One Biopharmaceuticals2.4346 of 5 stars$12.77+4.6%$35.86+180.8%-10.3%$1.29B$101.95M-12.4060ANIPANI Pharmaceuticals4.4721 of 5 stars$60.10+2.5%$77.71+29.3%+7.9%$1.26B$486.82M-109.19600Analyst DowngradeShort Interest ↓ARVNArvinas2.7563 of 5 stars$18.130.0%$63.50+250.2%-55.6%$1.25B$78.50M-3.89420Gap UpRCUSArcus Biosciences1.8181 of 5 stars$13.52+2.7%$34.00+151.6%-14.7%$1.24B$117M-4.29500OCULOcular Therapeutix3.4053 of 5 stars$7.80-2.1%$16.71+114.3%+53.4%$1.23B$58.44M-5.91230SNDXSyndax Pharmaceuticals3.5466 of 5 stars$14.26+0.1%$36.20+153.9%-32.5%$1.22BN/A-3.93110Short Interest ↑CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Praxis Precision Medicines Alternatives Xencor Alternatives Ardelyx Alternatives Day One Biopharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Arvinas Alternatives Arcus Biosciences Alternatives Ocular Therapeutix Alternatives Syndax Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDT) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
